Interestingly, PPARG agonists have been used in the treatment of dyslipidemia and hyperglycemia [3], [4] and many insulin sensitizing drugs targetting PPARG are designed in the treatment of diabetes as a way to lower serum glucose without increasing pancreatic insulin secretion [5]. Here, INS is linked to metabolic syndrome.